Analysis of the iron states in iron-containing pharmaceutical products using Mössbauer spectroscopy.

Autor: Alenkina IV; Institute of Physics and Technology, Ural Federal University, Ekaterinburg 620002, Russian Federation., Chukin AV; Institute of Physics and Technology, Ural Federal University, Ekaterinburg 620002, Russian Federation., Leitus G; Department of Chemical Research Support, Weizmann Institute of Science, Rehovot, Israel., Denisova OV; Institute of Physics and Technology, Ural Federal University, Ekaterinburg 620002, Russian Federation., Gracheva M; Laboratory of Nuclear Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, Hungary; Hevesy Gyorgy Doctoral School of Chemistry, Eötvös Loránd University, Budapest, Hungary., Felner I; Racah Institute of Physics, The Hebrew University, Jerusalem 91904, Israel., Kuzmann E; Laboratory of Nuclear Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, Hungary., Homonnay Z; Laboratory of Nuclear Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, Hungary., Oshtrakh MI; Institute of Physics and Technology, Ural Federal University, Ekaterinburg 620002, Russian Federation. Electronic address: oshtrakh@gmail.com.
Jazyk: angličtina
Zdroj: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Jan 05; Vol. 237, pp. 115745. Date of Electronic Publication: 2023 Sep 22.
DOI: 10.1016/j.jpba.2023.115745
Abstrakt: Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon® with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex® and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by 57 Fe Mössbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by Mössbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Michael I. Oshtrakh reports financial support was provided by the Ministry of Science and Higher Education of the Russian Federation. Irina V. Alenkina reports financial support was provided by the Ministry of Science and Higher Education of the Russian Federation. There are no conflicts of interest.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: